论文部分内容阅读
作者观察了39例乳癌和29例恶性黑色素瘤的细胞免疫资料。在肿瘤手术后2～4周和特异性肿瘤疫苗免疫刺激后8周,分别测定了T/B淋巴细胞比例和植物血凝素、乳癌抗原(BCA)以及黑色素瘤抗原(MA)刺激后的淋转率。可发现明显不同的结果。小乳癌不激发宿主的免疫反应,但小黑色素瘤伴有免疫刺激状态。在免疫治疗8周后,乳癌病人的淋转率提示显著的免疫刺激,而黑色素瘤病人的淋转率显示免疫刺激转为正常反应。Ⅱ期肿瘤病人(指伴部分淋巴结转移,但无远处转移)的结果很不相同:乳癌者显示免疫刺激,但在免疫治疗后并不改变;黑色素瘤者显示低正常免疫反应,免疫治疗后则转变为高正常免
The authors observed cellular immune data from 39 cases of breast cancer and 29 cases of malignant melanoma. T/B lymphocyte ratios and thrombocytopenia, breast cancer antigen (BCA), and melanoma antigen (MA) stimulation were measured at 2 to 4 weeks after tumor surgery and 8 weeks after the specific tumor vaccine immunostimulation. Conversion rate. Obviously different results can be found. Small breast cancer does not elicit an immune response from the host, but small melanomas are accompanied by immune stimuli. After 8 weeks of immunotherapy, the rate of conversion of breast cancer patients showed significant immunostimulation, whereas the rate of conversion of melanoma patients showed that the immune stimulation turned to normal responses. Stage II tumor patients (referring to some lymph node metastases, but no distant metastases) have very different results: breast cancer patients showed immune stimulation, but did not change after immunotherapy; melanoma patients showed low normal immune response, after immunotherapy Change to high normal free